Brief: Lumos Pharma Reports Initiation Of Phase 2B OraGrowtH210 Trial
10/11/2020 21:07
Nov 10 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA ANNOUNCES THE INITIATION OF PHASE 2B
ORAGROWTH210
TRIAL AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
* LUMOS PHARMA INC - ANTICIPATES DATA READ OUT FOR
ORAGROWTH210
TRIAL MID-YEAR 2022
* LUMOS PHARMA - EXPECTS CASH ON HAND SUFFICIENT TO FUND
CURRENT
OPERATIONS THROUGH READ-OUT OF PHASE 2B ORAGROWTH210 TRIAL,
COMPLETION OF ORAGROWTH212 TRIAL
Source text for Eikon: ID:nGNX6kfdDx
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)